Canadian Institute For Knowledge Development
  • Register
  • Login

Canadian Journal of Medicine

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 2, Issue 1
  3. Author

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Indexing and Abstracting

Peer Review Process

News

Two-Phase Immune Responses of COVID-19 and Therapeutic Approaches

    Seyed Hassan Saadat

Canadian Journal of Medicine, 2020, Volume 2, Issue 1, Pages 0-0
10.33844/cjm.2020.60492

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

The novel coronavirus disease 2019 spread rapidly worldwide and disease was announced a pandemic by the WHO. Standard therapeutic strategy against COVID-19 is lacking. Regarding to the two-phase pathogenesis of the COVID-19 (immune defense-based protective and postinitial inflammation-driven damaging phases, different therapeutic regimens including antiviral agents (e.g., lopinavir/ritonavir, remdesivir, ribavirin, oseltamivir, and sofosbuvir, etc.), some antibiotics and immunomodulatory (chloroquine/hydroxychloroquine) and anti inflammatory agents (corticosteroids) have been considered in hospitals for COVID-19 patients, but balancing their
benefits and potential risk is of great importance [1-7].
Immune-boosting strategies (e.g., anti-sera or pegylated IFNα) and antiviral therapy may be of great importance in the initial phase or non-severe stages, while immunosuppressive or immunomodulatory approaches can be used for halting tissue damage and managing the symptoms in the inflammatory phase. There are conflicting results in prescribing corticosteroids or immunomodulation for COVID-19 patients due to paradoxical negative effects (risk of death, secondary bacterial infections and longer hospitalization) [8-9]. Activation of coagulation pathways
is also associated with increased proinflammatory cytokines, resulting in multiorgan injury. Severe COVID‐19 had disseminated intravascular coagulation, leading to the risk of venous thromboembolism [10], where naproxen (for antiplatelet and anti-inflammatory and anticoagulative effects) and low molecular weight heparin (LMWH; anti-inflammatory properties) may be considered for patients. It has been suggested that LMWH is contemplated because of concerns because of the presence of thrombi in the pulmonary circulation for those in patients with
raised d-dimer.
However, effective therapeutic approach requires balancing harmful and beneficial effects of regimens, to be prescribed by precision. Also, two-phase pathophysiology and immune responses of COVID-19 should not be underemphasized for treatment of patients.
Keywords:
  • PDF (192 K)
  • XML
Seyed Hassan Saadat (2020). Two-Phase Immune Responses of COVID-19 and Therapeutic Approaches. Canadian Journal of Medicine, 2(1), 0-0. doi: 10.33844/cjm.2020.60492
Seyed Hassan Saadat. "Two-Phase Immune Responses of COVID-19 and Therapeutic Approaches". Canadian Journal of Medicine, 2, 1, 2020, 0-0. doi: 10.33844/cjm.2020.60492
Seyed Hassan Saadat (2020). 'Two-Phase Immune Responses of COVID-19 and Therapeutic Approaches', Canadian Journal of Medicine, 2(1), pp. 0-0. doi: 10.33844/cjm.2020.60492
Seyed Hassan Saadat Two-Phase Immune Responses of COVID-19 and Therapeutic Approaches. Canadian Journal of Medicine, 2020; 2(1): 0-0. doi: 10.33844/cjm.2020.60492
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 511
  • PDF Download: 332
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus